Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
European Journal of Radiology|October 30, 2020
Preablation three-dimensional ultrasonography can predict therapeutic effect and local tumor progression after radiofrequency ablation for hepatocellular carcinomaYukako Matsuki, Tomomitsu Matono, Masahiko Koda, et al.
BMC Medical Imaging|August 10, 2021
A vein-viewing application enabled detecting abdominal wall varices related to the presence of non-treated gastroesophageal varices: a cross-sectional studyYoshiki Hoshino, Takaaki Sugihara, Suguru Ikeda, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|December 12, 2022
[Small duct primary sclerosing cholangitis diagnosed after fever and liver disorder: a case report]Takuya Kihara, Takaaki Sugihara, Suguru Ikeda, et al.
Diagnostics (Basel, Switzerland)|May 27, 2023
Identification and Quantification of Jaundice by Trans-Conjunctiva Optical Imaging Using a Human Brain-like Algorithm: A Cross-Sectional StudyTakuya Kihara, Takaaki Sugihara, Suguru Ikeda, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-UpSuguru Ikeda, Takaaki Sugihara, Takuya Kihara, et al.
Oncology Letters|August 30, 2021
Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent mannerTakashi Hasegawa, Takaaki Sugihara, Yoshiki Hoshino, et al.
Yonago Acta Medica|November 30, 2020
Erratum for Ikeda et al., "Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease"Suguru Ikeda, Takaaki Sugihara, Yoshiki Hoshino, et al.
Yonago Acta Medica|September 5, 2020
Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver DiseaseSuguru Ikeda, Takaaki Sugihara, Yoshiki Hoshino, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|July 7, 2017
Compliance and problems with the surveillance program for HCC diagnosisJun-Ichi Okano, Yukako Matsuki, Ran Nagahara, et al.
Yonago Acta Medica|April 10, 2019
Gene Expression Analysis of the Activating Factor 3/Nuclear Protein 1 Axis in a Non-alcoholic Steatohepatitis Mouse ModelRan Nagahara, Tomomitsu Matono, Takaaki Sugihara, et al.
Pageof 2